Citizens JMP raised the firm’s price target on Taysha Gene Therapies (TSHA) to $6 from $5 and keeps an Outperform rating on the shares. Taysha Gene Therapies reported positive clinical data from Part A of the REVEAL adult/ adolescent and pediatric cohorts evaluating TSHA-102 in females with Rett syndrome at the low dose and at the high dose and also announced written alignment with the FDA on the design of the pivotal study which will initiate in 3Q25, the analyst tells investors in a research note. Citizens views the data around the objectivity of the endpoint as a positive, along with the alignment with the FDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies Announces Pivotal Trial Design for TSHA-102
- Taysha Gene Therapies announces Part B trial design for TSHA-102
- Taysha Gene Therapies announces common stock offering, no amount given
- Positive Developments and Strategic Moves Position Taysha Gene Therapies for Success with TSHA-102
- Taysha Gene Therapies price target raised to $9 from $8 at Canaccord